162 related articles for article (PubMed ID: 16943301)
1. Tracking of peptide-specific CD4+ T-cell responses after an acute resolving viral infection: a study of parvovirus B19.
Kasprowicz V; Isa A; Tolfvenstam T; Jeffery K; Bowness P; Klenerman P
J Virol; 2006 Nov; 80(22):11209-17. PubMed ID: 16943301
[TBL] [Abstract][Full Text] [Related]
2. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
[TBL] [Abstract][Full Text] [Related]
3. T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.
Franssila R; Auramo J; Modrow S; Möbs M; Oker-Blom C; Käpylä P; Söderlund-Venermo M; Hedman K
Clin Exp Immunol; 2005 Oct; 142(1):53-61. PubMed ID: 16178856
[TBL] [Abstract][Full Text] [Related]
4. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
5. Aberrant cellular immune responses in humans infected persistently with parvovirus B19.
Isa A; Norbeck O; Hirbod T; Lundqvist A; Kasprowicz V; Bowness P; Klenerman P; Broliden K; Tolfvenstam T
J Med Virol; 2006 Jan; 78(1):129-33. PubMed ID: 16299714
[TBL] [Abstract][Full Text] [Related]
6. T lymphocyte responses against human parvovirus B19: small virus, big response.
Klenerman P; Tolfvenstam T; Price DA; Nixon DF; Broliden K; Oxenius A
Pathol Biol (Paris); 2002 Jun; 50(5):317-25. PubMed ID: 12116850
[TBL] [Abstract][Full Text] [Related]
7. Persistent parvovirus B19 infection detected by specific CD4+ T-cell responses in a patient with hepatitis and polyarthritis.
Pongratz G; Lindner J; Modrow S; Schimanski S; Schölmerich J; Fleck M
J Intern Med; 2009 Sep; 266(3):296-301. PubMed ID: 19549095
[TBL] [Abstract][Full Text] [Related]
8. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins.
Manaresi E; Zuffi E; Gallinella G; Gentilomi G; Zerbini M; Musiani M
J Med Virol; 2001 May; 64(1):67-73. PubMed ID: 11285571
[TBL] [Abstract][Full Text] [Related]
9. Microsphere-Based IgM and IgG Avidity Assays for Human Parvovirus B19, Human Cytomegalovirus, and Toxoplasma gondii.
Wang Y; Hedman L; Nurmi V; Ziemele I; Perdomo MF; Söderlund-Venermo M; Hedman K
mSphere; 2020 Mar; 5(2):. PubMed ID: 32188754
[TBL] [Abstract][Full Text] [Related]
10. Detection of IgE anti-parvovirus B19 and increased CD23+ B cells in parvovirus B19 infection: relation to Th2 cytokines.
Bluth MH; Norowitz KB; Chice S; Shah VN; Nowakowski M; Josephson AS; Durkin HG; Smith-Norowitz TA
Clin Immunol; 2003 Aug; 108(2):152-8. PubMed ID: 12921761
[TBL] [Abstract][Full Text] [Related]
11. Increased Numbers of CD4
Naciute M; Maciunaite G; Mieliauskaite D; Rugiene R; Zinkeviciene A; Mauricas M; Murovska M; Girkontaite I
In Vivo; 2017; 31(2):181-185. PubMed ID: 28358698
[TBL] [Abstract][Full Text] [Related]
12. Impaired gamma interferon responses against parvovirus B19 by recently infected children.
Corcoran A; Doyle S; Waldron D; Nicholson A; Mahon BP
J Virol; 2000 Nov; 74(21):9903-10. PubMed ID: 11024117
[TBL] [Abstract][Full Text] [Related]
13. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
Franssila R; Hedman K
Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
[TBL] [Abstract][Full Text] [Related]
14. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties.
Lunardi C; Tiso M; Borgato L; Nanni L; Millo R; De Sandre G; Severi AB; Puccetti A
Eur J Immunol; 1998 Mar; 28(3):936-48. PubMed ID: 9541589
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus.
van Elsacker-Neile AM; Kroon FP; van der Ende ME; Salimans MM; Spaan WJ; Kroes AC
Clin Infect Dis; 1996 Dec; 23(6):1255-60. PubMed ID: 8953068
[TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women.
Hemauer A; Gigler A; Searle K; Beckenlehner K; Raab U; Broliden K; Wolf H; Enders G; Modrow S
J Med Virol; 2000 Jan; 60(1):48-55. PubMed ID: 10568763
[TBL] [Abstract][Full Text] [Related]
17. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
Corcoran A; Mahon BP; Doyle S
J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
[TBL] [Abstract][Full Text] [Related]
18. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG.
Kerr S; O'Keeffe G; Kilty C; Doyle S
J Med Virol; 1999 Feb; 57(2):179-85. PubMed ID: 9892405
[TBL] [Abstract][Full Text] [Related]
19. Parvovirus B19 quiescence during the course of human immunodeficiency virus infection in persons with hemophilia.
Goedert JJ; Erdman DD; Konkle BA; Török TJ; Lederman MM; Kleinert D; Mandalaki T; Kessler CM; Anderson LJ; Luban NL
Am J Hematol; 1997 Dec; 56(4):248-51. PubMed ID: 9395187
[TBL] [Abstract][Full Text] [Related]
20. Parvovirus B19 infection modulates the levels of cytokines in the plasma of rheumatoid arthritis patients.
Naciute M; Mieliauskaite D; Rugiene R; Maciunaite G; Mauricas M; Murovska M; Girkontaite I
Cytokine; 2017 Aug; 96():41-48. PubMed ID: 28288327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
